vs

Side-by-side financial comparison of Genius Sports Ltd (GENI) and SiriusPoint Ltd (SPNT). Click either name above to swap in a different company.

SiriusPoint Ltd is the larger business by last-quarter revenue ($973.7M vs $510.9M, roughly 1.9× Genius Sports Ltd). SiriusPoint Ltd runs the higher net margin — 25.1% vs -12.3%, a 37.4% gap on every dollar of revenue. Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 19.2%).

Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.

SiriusPoint Ltd is a global specialty insurance and reinsurance provider based in Pembroke, Bermuda. It offers property, casualty, specialty line coverages and alternative capital solutions, serving commercial clients and risk carriers across North America, Europe, Asia Pacific and other key markets, focusing on rigorous underwriting and stable risk-adjusted returns.

GENI vs SPNT — Head-to-Head

Bigger by revenue
SPNT
SPNT
1.9× larger
SPNT
$973.7M
$510.9M
GENI
Higher net margin
SPNT
SPNT
37.4% more per $
SPNT
25.1%
-12.3%
GENI
Faster 2-yr revenue CAGR
GENI
GENI
Annualised
GENI
129.2%
19.2%
SPNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GENI
GENI
SPNT
SPNT
Revenue
$510.9M
$973.7M
Net Profit
$-63.0M
$244.1M
Gross Margin
25.2%
Operating Margin
-11.5%
28.8%
Net Margin
-12.3%
25.1%
Revenue YoY
58.9%
Net Profit YoY
1535.9%
EPS (diluted)
$1.92

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENI
GENI
SPNT
SPNT
Q4 25
$510.9M
$973.7M
Q3 25
$335.4M
$755.9M
Q2 25
$215.2M
$748.2M
Q1 25
$119.7M
$727.3M
Q4 24
$413.0M
$612.8M
Q3 24
$285.8M
$562.2M
Q2 24
$184.1M
$743.3M
Q1 24
$97.2M
$685.5M
Net Profit
GENI
GENI
SPNT
SPNT
Q4 25
$-63.0M
$244.1M
Q3 25
$90.8M
Q2 25
$-47.3M
$63.2M
Q1 25
$-25.5M
$61.6M
Q4 24
$-85.5M
$-17.0M
Q3 24
$-47.1M
$8.5M
Q2 24
$-35.5M
$113.9M
Q1 24
$-25.2M
$94.8M
Gross Margin
GENI
GENI
SPNT
SPNT
Q4 25
25.2%
Q3 25
24.2%
Q2 25
19.1%
Q1 25
10.7%
Q4 24
16.7%
Q3 24
20.5%
Q2 24
18.6%
Q1 24
9.8%
Operating Margin
GENI
GENI
SPNT
SPNT
Q4 25
-11.5%
28.8%
Q3 25
-15.3%
14.7%
Q2 25
-21.0%
10.0%
Q1 25
-20.3%
10.4%
Q4 24
-18.0%
-2.1%
Q3 24
-13.9%
2.0%
Q2 24
-16.8%
17.4%
Q1 24
-23.7%
15.4%
Net Margin
GENI
GENI
SPNT
SPNT
Q4 25
-12.3%
25.1%
Q3 25
12.0%
Q2 25
-22.0%
8.4%
Q1 25
-21.3%
8.5%
Q4 24
-20.7%
-2.8%
Q3 24
-16.5%
1.5%
Q2 24
-19.3%
15.3%
Q1 24
-25.9%
13.8%
EPS (diluted)
GENI
GENI
SPNT
SPNT
Q4 25
$1.92
Q3 25
$0.73
Q2 25
$0.50
Q1 25
$0.49
Q4 24
$-0.05
Q3 24
$0.03
Q2 24
$0.57
Q1 24
$0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENI
GENI
SPNT
SPNT
Cash + ST InvestmentsLiquidity on hand
$280.6M
$731.2M
Total DebtLower is stronger
$688.6M
Stockholders' EquityBook value
$724.5M
$2.5B
Total Assets
$1.1B
$12.6B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENI
GENI
SPNT
SPNT
Q4 25
$280.6M
$731.2M
Q3 25
$110.2M
$582.4M
Q2 25
$110.2M
$732.4M
Q1 25
$110.2M
$740.3M
Q4 24
$100.3M
$682.0M
Q3 24
$100.3M
$640.7M
Q2 24
$100.3M
$598.1M
Q1 24
$100.3M
$867.5M
Total Debt
GENI
GENI
SPNT
SPNT
Q4 25
$688.6M
Q3 25
$682.5M
Q2 25
$678.4M
Q1 25
$663.5M
Q4 24
$639.1M
Q3 24
$660.5M
Q2 24
$648.6M
Q1 24
$770.6M
Stockholders' Equity
GENI
GENI
SPNT
SPNT
Q4 25
$724.5M
$2.5B
Q3 25
$572.4M
$2.2B
Q2 25
$572.4M
$2.1B
Q1 25
$572.4M
$2.0B
Q4 24
$573.0M
$1.9B
Q3 24
$573.0M
$2.7B
Q2 24
$573.0M
$2.7B
Q1 24
$573.0M
$2.6B
Total Assets
GENI
GENI
SPNT
SPNT
Q4 25
$1.1B
$12.6B
Q3 25
$792.3M
$12.5B
Q2 25
$792.3M
$12.4B
Q1 25
$792.3M
$12.3B
Q4 24
$775.7M
$12.5B
Q3 24
$775.7M
$12.7B
Q2 24
$775.7M
$12.8B
Q1 24
$775.7M
$13.1B
Debt / Equity
GENI
GENI
SPNT
SPNT
Q4 25
0.28×
Q3 25
0.31×
Q2 25
0.32×
Q1 25
0.33×
Q4 24
0.33×
Q3 24
0.25×
Q2 24
0.24×
Q1 24
0.30×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENI
GENI
SPNT
SPNT
Operating Cash FlowLast quarter
$81.9M
$-26.4M
Free Cash FlowOCF − Capex
$69.6M
FCF MarginFCF / Revenue
13.6%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
-0.11×
TTM Free Cash FlowTrailing 4 quarters
$33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENI
GENI
SPNT
SPNT
Q4 25
$81.9M
$-26.4M
Q3 25
$-4.8M
$155.6M
Q2 25
$-1.2M
$62.1M
Q1 25
$-14.6M
$-88.9M
Q4 24
$14.9M
$107.7M
Q3 24
$-9.2M
$58.1M
Q2 24
$-149.9M
Q1 24
$58.8M
Free Cash Flow
GENI
GENI
SPNT
SPNT
Q4 25
$69.6M
Q3 25
$-14.2M
Q2 25
$-5.8M
Q1 25
$-16.0M
Q4 24
$11.3M
Q3 24
$-11.6M
Q2 24
Q1 24
FCF Margin
GENI
GENI
SPNT
SPNT
Q4 25
13.6%
Q3 25
-4.2%
Q2 25
-2.7%
Q1 25
-13.4%
Q4 24
2.7%
Q3 24
-4.1%
Q2 24
Q1 24
Capex Intensity
GENI
GENI
SPNT
SPNT
Q4 25
2.4%
Q3 25
2.8%
Q2 25
2.1%
Q1 25
1.2%
Q4 24
0.9%
Q3 24
0.9%
Q2 24
Q1 24
Cash Conversion
GENI
GENI
SPNT
SPNT
Q4 25
-0.11×
Q3 25
1.71×
Q2 25
0.98×
Q1 25
-1.44×
Q4 24
Q3 24
6.84×
Q2 24
-1.32×
Q1 24
0.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons